Skip to main content
OpenTrials

Clinical trial condition

Relapsing Multiple Sclerosis

Explore clinical trials studying Relapsing Multiple Sclerosis. Study availability and eligibility vary by location and protocol.

69 public trials 9 recruiting studies
Refine in advanced search Browse all conditions

Relapsing Multiple Sclerosis trial results

Completed

A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab

NCT04667117

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +5 more
Locations
  • Hope Research Institute Center Neurology and Spine Phoenix, Arizona, United States
  • Infinity Clinical Research LLC Hollywood, Florida, United States
  • The MS Center for Innovation in Care St Louis, Missouri, United States
View Trial Details
Completed

Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients

NCT03623243

Conditions
Advancing Multiple Sclerosis, Autoimmune Diseases, Autoimmune Diseases of the Nervous System, +6 more
Locations
  • Novartis Investigative Site Birmingham, Alabama, United States
  • Novartis Investigative Site Cullman, Alabama, United States
  • Alabama Neurology Associates Homewood, Alabama, United States
  • Novartis Investigative Site Tucson, Arizona, United States
View all 55 locations
View Trial Details
Completed

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis

NCT01412333

Conditions
Relapsing Multiple Sclerosis
Locations
  • Hope Research Institute Phoenix, Arizona, United States
  • HonorHealth Neurology Scottsdale, Arizona, United States
  • Territory Neurology and Research Institute Tucson, Arizona, United States
  • Collaborative Neuroscience Research, LLC Long Beach, California, United States
View all 165 locations
View Trial Details
Completed

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis

NCT01247324

Conditions
Relapsing Multiple Sclerosis
Locations
  • 21st Century Neurology Phoenix, Arizona, United States
  • Mercy Medical Group Carmichael, California, United States
  • Scripps Clinic La Jolla, California, United States
  • MS Center of California Laguna Hills, California, United States
View all 142 locations
View Trial Details
Completed

A Multi-Center, Open-Label Long-Term Extension Study of CNM-Au8 In Patients With Stable Relapsing Multiple Sclerosis

NCT04626921

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Cranial Nerve Diseases, +9 more
Locations
  • Sydney Brain Mind Centre Camperdown, New South Wales, Australia
  • John Hunter Hospital New Lambton Heights, New South Wales, Australia
  • Princess Alexandra Hospital Woolloongabba, Queensland, Australia
  • Menzies Institute for Medical Research Hobart, TAZ, Australia
View Trial Details
Completed

To Evaluate the Safety and Efficacy of Teriflunomide in Patients With Relapsing Forms of Multiple Sclerosis

NCT03856619

Conditions
Relapsing Multiple Sclerosis
Locations
  • Investigational Site Number :024 Ahmedabad, India
  • Investigational Site Number :017 Bengaluru, India
  • Investigational Site Number :001 Chandigarh, India
  • Investigational Site Number :023 Coimbatore, India
View all 14 locations
View Trial Details
Completed

A Multicenter Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab

NCT04847596

Conditions
COVID-19, Coronaviridae Infections, Coronavirus Infections, +10 more
Locations
  • Novartis Investigative Site Phoenix, Arizona, United States
  • Novartis Investigative Site Owosso, Michigan, United States
  • Novartis Investigative Site St Louis, Missouri, United States
  • Novartis Investigative Site Plainview, New York, United States
View Trial Details
Completed

Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab

NCT03249714

Conditions
Relapsing Multiple Sclerosis
Locations
  • Novartis Investigative Site Tōon, Ehime, Japan
  • Novartis Investigative Site Fukuoka, Japan
  • Novartis Investigative Site Sapporo, Hokkaido, Japan
  • Novartis Investigative Site Morioka, Iwate, Japan
View all 14 locations
View Trial Details

Related conditions